COIOSDeep risk insights through multi-disciplinary research across the globe
Cityscape at dusk with illuminated buildings, river, and winding roads
Item refines Peer-reviewed Added

Lecanemab in Chinese patients with Alzheimer's disease over 13 months of routine care

Among 122 Chinese patients with Alzheimer's disease treated with lecanemab, 84% held or improved their Clinical Dementia Rating stage at 13 months and two-thirds became amyloid-negative, but those whose amyloid fell most did not clearly improve most in cognition.

This prospective cohort followed 122 patients given lecanemab every two weeks at nine centres in Southwest China. Of these, 38.52% had mild cognitive impairment due to Alzheimer's disease (AD) and 40.98% had mild AD dementia. Treated patients had more favourable cognitive trajectories than propensity-matched local controls and an Alzheimer's Disease Neuroimaging Initiative natural-history cohort. At 13 months, 84.00% held or improved their Clinical Dementia Rating stage and 66.67% became amyloid-negative (Centiloid below 12). Amyloid reduction was not robustly linked to cognitive gain, and baseline clinical variables did not reliably predict response. Amyloid-related imaging abnormalities affected 10.66%, and the abstract does not say how many patients reached 13 months.

Why it is interesting: It adds 13-month real-world data on an anti-amyloid drug outside trial populations. Patients stopped mostly because repeated infusions were inconvenient, not because of safety concerns.

Source
Journal of Neurology, 18 November 2026
Paper
Thirteen-month real-world effectiveness and safety of lecanemab in Chinese patients with Alzheimer’s disease: integrating objective clinical outcomes and caregiver-reported experiences
Authors
Chen S, Gao X, Li F, Ou R, Wei Q, Li C et al.
DOI
10.1007/s00415-026-14270-6
Type
Peer-reviewed article
Design
Prospective multicentre observational cohort, 122 lecanemab-treated patients across nine centres in Southwest China, 222 follow-up visits over 13 months, propensity-matched local and ADNI controls
Verdict
Refines prior evidence
Driver
Dementia

Other drivers in Health today